1.Clinical efficacy of chloroquine versus artemether-lumefantrine for Plasmodium vivax treatment in Thailand.
Srivicha KRUDSOOD ; Noppadon TANGPUKDEE ; Sant MUANGNOICHAROEN ; Vipa THANACHARTWET ; Nutthanej LUPLERTLOP ; Siripan SRIVILAIRIT ; Polrat WILAIRATANA ; Shigeyuki KANO ; Pascal RINGWALD ; Sornchai LOOAREESUWAN
The Korean Journal of Parasitology 2007;45(2):111-114
Chloroquine remains the drug of choice for the treatment of vivax malaria in Thailand. Mixed infections of falciparum and vivax malaria are also common in South-East Asia. Laboratory confirmation of malaria species is not generally available. This study aimed to find alternative regimens for treating both malaria species by using falciparum antimalarial drugs. From June 2004 to May 2005, 98 patients with Plasmodium vivax were randomly treated with either artemether-lumefantrine (n = 47) or chloroquine (n = 51). Both treatments were followed by 15 mg of primaquine over 14 days. Adverse events and clinical and parasitological outcomes were recorded and revealed similar in both groups. The cure rate was 97.4% for the artemether-lumefantrine treated group and 100% for the chloroquine treated group. We concluded that the combination of artemether-lumefantrine and primaquine was well tolerated, as effective as chloroquine and primaquine, and can be an alternative regimen for treatment of vivax malaria especially in the event that a mixed infection of falciparum and vivax malaria could not be ruled out.
Adolescent
;
Aged
;
Animals
;
Antimalarials/adverse effects/*therapeutic use
;
Artemisinins/adverse effects/*therapeutic use
;
Chloroquine/adverse effects/*therapeutic use
;
Drug Therapy, Combination
;
Ethanolamines/adverse effects/*therapeutic use
;
Female
;
Fluorenes/adverse effects/*therapeutic use
;
Humans
;
Malaria, Vivax/*drug therapy
;
Male
;
Middle Aged
;
Parasitemia
;
Plasmodium vivax/drug effects
;
Primaquine/therapeutic use
;
Thailand
;
Treatment Outcome
2.Beneficial effects of switching from beta-blockers to nebivolol on the erectile function of hypertensive patients.
Michael DOUMAS ; Alexandros TSAKIRIS ; Stella DOUMA ; Alkiviadis GRIGORAKIS ; Angelos PAPADOPOULOS ; Athina HOUNTA ; Sotirios TSIODRAS ; Dimitrios DIMITRIOU ; Helen GIAMARELLOU
Asian Journal of Andrology 2006;8(2):177-182
AIMTo investigate the effect of substituting beta-blockers with nebivolol on the erectile function of patients suffering from essential hypertension.
METHODSForty-four young and middle-aged men (31-65 years) with essential hypertension visited our outpatient clinic and took beta-blocker treatment (atenolol, metoprolol or bisoprolol) for more than 6 months. All the patients completed a questionnaire regarding erectile function (International Index for Erectile Function). Patients were then switched to an equipotent dose of nebivolol for 3 months and, at the end of this time period, filled out the same questionnaire.
RESULTSTwenty-nine out of the 44 (65.9%) patients who took beta-blockers (atenolol, metoprolol or bisoprolol) had exhibited erectile dysfunction (ED). Their systolic and diastolic blood pressure did not change significantly with the treatment switch. In 20 out of these 29 (69%) patients, a significant improvement in the erectile function score was exhibited after 3 months of nebivolol administration, and in 11 of these 20 patients, erectile function was normalized.
CONCLUSIONNebivolol seems to have a beneficial effect on ED (possibly due to increased nitric oxide availability); however, further prospective, randomized, placebo-controlled studies are needed to confirm the beneficial effects of nebivolol.
Adrenergic beta-Antagonists ; adverse effects ; therapeutic use ; Adult ; Aged ; Antihypertensive Agents ; adverse effects ; Benzopyrans ; therapeutic use ; Erectile Dysfunction ; chemically induced ; drug therapy ; Ethanolamines ; therapeutic use ; Humans ; Hypertension ; complications ; Male ; Middle Aged ; Nebivolol ; Surveys and Questionnaires